The analysis of the two sets separately showed a marginally significant increased survival for patients with lower CTGF expression from the new peripheral blood specimens (log rank, p=0.04). == Nucleoside Transporter Manifestation == High expression (2+ by immunohistochemistry) of hENT1, hCNT3, dCK cytoplasmic, and dCK nuclear were noted in 54%, 44%, 33%, and 33% of patients respectively (Table 4). 54%, 33% and 44% of individuals, respectively, but were not significantly correlated with end result. Higher manifestation CTGF individuals showed a tendency for shorter overall survival. This routine is without adequate activity to warrant further testing. CTGF manifestation may forecast response and overall survival. Keywords:Clofarabine, Cytarabine, Acute Lymphocytic Leukemia == Intro == The prognosis of child years acute lymphocytic leukemia (ALL) offers improved significantly over the last decade with 8090% of children being cured. Regrettably, the prognosis for adults with ALL remains poor. More than half of adults will either be refractory to their initial treatment or will relapse. At the time of relapse, the only curative treatment is definitely allogeneic hematopoietic cell transplant (HCT). However, most individuals will require re-induction therapy prior to proceeding to HCT. Currently, no standard routine Daidzin for re-induction is present. Most salvage regimens incorporate Daidzin medicines that are used in the initial treatment and total remission (CR) rates possess generally been disappointing: 37% with high dose cytarabine, 1015% with etoposide (Hoelzer, 1991;Hoelzeret al, 2002). Consequently, novel treatments are needed. Clofarabine, a nucleoside analog, was recently FDA-approved for the treatment of pediatric relapsed/refractory ALL based on the results of two phase 2 multi-center tests. The overall response rate [total Daidzin remission (CR) + partial remission (PR)] was 31% (Jehaet al, 2004). The median quantity of prior treatment regimens that individuals received was three, and 39% of individuals experienced undergone prior allogeneic HCT. Clofarabine requires intracellular phosphorylation by deoxycytidine kinase to be metabolized to the triphosphate form which is necessary for its cytotoxic effect (Gandhiet al,2003;Parkeret al,1999). Compared to the additional nucleoside analogs (fludarabine and cladribine), clofarabine has a high affinity for deoxycytidine kinase and is a potent inhibitor of both DNA polymerase and ribonucleotide reductase (Gandhiet al,2003;Parkeret al,1991;Parkeret al,1988; Zieet al,1995; Zieet al,1996). Inside a Phase 2 study of clofarabine in adults with active leukemia, 12 individuals with ALL were treated (Kantarjianet al, 2003). The response rate was 17%, suggesting modest solitary agent activity of clofarabine in adults with relapsed/refractory ALL. Based upon the solitary agent activity observed with clofarabine in several populations of individuals with relapsed or refractory leukemia, efforts were carried out to combine clofarabine with additional antileukemic providers. Cytarabine is active in the treatment of ALL. Clofarabine and cytarabine target different methods in DNA synthesis, are synergisticin vitro, and have nonoverlapping toxicities, making this combination potentially encouraging for the treatment of relapsed/refractory ALL (Gandhiet al1997;Cooperet al, 2003;Faderlet al, 2005). Clofarabine pre-treatment of cell lines raises cytarabine triphosphate build up in cells (Cooperet al,2005). By inhibiting ribonucleotide reductase, clofarabine causes depletion of normal deoxynucleotides (Parkeret al,1999;Parkeret al,1991; Parkeret al,2988;Xieet al,1995;Xieet al,1996). This, in turn, prospects to a decrease in opinions inhibition of deoxycytidine kinase and allows for increased production and build up of cytarabine triphosphate (Faderlet al,2005). Faderl and associates previously determined the maximum tolerated dose of clofarabine in combination with cytarabine inside a Phase 1/2 study (Faderlet al, 2005). Based on the above observations, we carried out a Phase 2 study of clofarabine/cytarabine in adult individuals with relapsed/refractory ALL. In addition to evaluating effectiveness, we also assessed connective tissue growth factor (CTGF) manifestation and RIEG nucleoside transporter manifestation (hENT1, dCK, hCNT3) in pre-treatment samples to see if their manifestation correlated with response. CTGF is definitely overexpressed in both pediatric and adult ALL and is associated with a poor end result inde novoALL (Sala-Torraet al,2007). Transport of nucleoside analogs such as clofarabine across the plasma membrane of the tumor may determine their cytotoxicity; therefore, nucleoside transporter manifestation may impact response to therapy. == MATERIALS AND METHODS == Patients were treated at Southwest Oncology Group (SWOG) organizations from February 2007 through July 2008. Clofarabine was supplied by the Genzyme Corporation. All individuals offered authorized educated consent in accordance with institutional and federal recommendations. This study.
The analysis of the two sets separately showed a marginally significant increased survival for patients with lower CTGF expression from the new peripheral blood specimens (log rank, p=0